Found: 13
Select item for more details and to access through your institution.
Diagnostic efficacy of liquid-based cytology for solid pancreatic lesion samples obtained with endoscopic ultrasound-guided fine-needle aspiration: Propensity score-matched analysis.
- Published in:
- Digestive Endoscopy, 2017, v. 29, n. 5, p. 608, doi. 10.1111/den.12827
- By:
- Publication type:
- Article
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-34962-7
- By:
- Publication type:
- Article
The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study.
- Published in:
- Internal Medicine, 2023, v. 62, n. 11, p. 1573, doi. 10.2169/internalmedicine.9689-22
- By:
- Publication type:
- Article
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 8, p. 1073, doi. 10.1007/s10147-023-02354-6
- By:
- Publication type:
- Article
Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 5, p. 941, doi. 10.1007/s10147-021-01859-2
- By:
- Publication type:
- Article
Horizontal transmission of de novo hepatitis B between spouses: A case report.
- Published in:
- Hepatology Research, 2015, v. 45, n. 8, p. 933, doi. 10.1111/hepr.12422
- By:
- Publication type:
- Article
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-65689-8
- By:
- Publication type:
- Article
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-63172-y
- By:
- Publication type:
- Article
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
- Published in:
- 2022
- By:
- Publication type:
- journal article
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study.
- Published in:
- Oncology, 2023, v. 101, n. 1, p. 22, doi. 10.1159/000527176
- By:
- Publication type:
- Article
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-46924-0
- By:
- Publication type:
- Article